Secretome Analysis of an Osteogenic Prostate Tumor Identifies Complex Signaling Networks Mediating Cross-talk of Cancer and Stromal Cells Within the Tumor Microenvironment*

A distinct feature of human prostate cancer (PCa) is the development of osteoblastic (bone-forming) bone metastases. Metastatic growth in the bone is supported by factors secreted by PCa cells that activate signaling networks in the tumor microenvironment that augment tumor growth. To better understand these signaling networks and identify potential targets for therapy of bone metastases, we characterized the secretome of a patient-derived xenograft, MDA-PCa-118b (PCa-118b), generated from osteoblastic bone lesion. PCa-118b induces osteoblastic tumors when implanted either in mouse femurs or subcutaneously. To study signaling molecules critical to these unique tumor/microenvironment-mediated events, we performed mass spectrometry on conditioned media of isolated PCa-118b tumor cells, and identified 26 secretory proteins, such as TGF-β2, GDF15, FGF3, FGF19, CXCL1, galectins, and β2-microglobulin, which represent both novel and previously published secreted proteins. RT-PCR using human versus mouse-specific primers showed that TGFβ2, GDF15, FGF3, FGF19, and CXCL1 were secreted from PCa-118b cells. TGFβ2, GDF15, FGF3, and FGF19 function as both autocrine and paracrine factors on tumor cells and stromal cells, that is, endothelial cells and osteoblasts. In contrast, CXCL1 functions as a paracrine factor through the CXCR2 receptor expressed on endothelial cells and osteoblasts. Thus, our study reveals a complex PCa bone metastasis secretome with paracrine and autocrine signaling functions that mediate cross-talk among multiple cell types within the tumor microenvironment.

[1]  N. Itoh,et al.  Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. , 2011, Journal of biochemistry.

[2]  C. Logothetis,et al.  A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation , 2008, Oncogene.

[3]  M. Ittmann,et al.  Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression , 2012, Clinical Cancer Research.

[4]  M. Mimeault,et al.  Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine‐1 in cancer , 2010, Journal of cellular physiology.

[5]  R. Satcher,et al.  BMP4 promotes prostate tumor growth in bone through osteogenesis. , 2011, Cancer research.

[6]  P. Russell,et al.  Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) Slows Cancer Development but Increases Metastases in TRAMP Prostate Cancer Prone Mice , 2012, PloS one.

[7]  M. V. Dinther,et al.  Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. , 2008, Kidney international.

[8]  E. Vazquez,et al.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. , 2008, The Journal of clinical investigation.

[9]  Payam Shahi,et al.  FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. , 2014, Cancer research.

[10]  Michael Ittmann,et al.  Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. , 2013, Cancer research.

[11]  M. Ittmann,et al.  FGFR1 is essential for prostate cancer progression and metastasis. , 2013, Cancer research.

[12]  Tomokazu Fukuda,et al.  BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.

[13]  S. Aaronson,et al.  Prostate cancer cells promote osteoblastic bone metastases through Wnts. , 2005, Cancer research.

[14]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[15]  S. Batra,et al.  Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway , 2010, Oncogene.

[16]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[17]  D. El-Rehim,et al.  Expression of Macrophage Inhibitory Cytokine-1 in Benign and Malignant Prostatic Tissues: Implications for Prostate Carcinogenesis and Progression of Prostate Cancer , 2010 .

[18]  Christine C. Wu,et al.  Proteomics of integral membrane proteins--theory and application. , 2007, Chemical reviews.

[19]  A. Kozubík,et al.  Growth/differentiation factor-15: prostate cancer suppressor or promoter? , 2012, Prostate Cancer and Prostatic Diseases.

[20]  Randall T Peterson,et al.  Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[21]  W. Wood,et al.  Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. , 1994, Science.

[22]  Brian Bierie,et al.  Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.

[23]  M. Burdick,et al.  Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. , 1999, The American journal of pathology.

[24]  Zhen Liu,et al.  High-throughput analysis of rat liver plasma membrane proteome by a nonelectrophoretic in-gel tryptic digestion coupled with mass spectrometry identification. , 2008, Journal of proteome research.

[25]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.

[26]  J. Clifton,et al.  Mass spectrometry-based analysis of rat liver and hepatocellular carcinoma Morris hepatoma 7777 plasma membrane proteome. , 2013, Analytical chemistry.

[27]  H. Gruber,et al.  CXC receptor knockout mice: characterization of skeletal features and membranous bone healing in the adult mouse. , 2011, Bone.

[28]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[29]  L. Yu-Lee,et al.  Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts , 2010, Oncogene.

[30]  James M. Woolven,et al.  Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. , 2006, Journal of medicinal chemistry.

[31]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[32]  Zuxiong Chen,et al.  Preferential production of latent transforming growth factor β‐2 by primary prostatic epithelial cells and its activation by prostate‐specific antigen , 2005, Journal of cellular physiology.

[33]  A. Jukkola-Vuorinen,et al.  Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases , 2007, Cancer Epidemiology Biomarkers & Prevention.

[34]  J. Kunz,et al.  16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. , 2007, Cancer research.

[35]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.